Loading clinical trials...

UNKNOWNPHASE2

Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades

Pain After Thoracoscopic Lung Surgery - the Effect of Intercostal Nerve Blockades With Standard Bupivacaine and Liposomal Bupivacaine - a Randomised Controlled Feasibility Trial

NCT05038007•Jannie Bisgaard Stæhr

View on ClinicalTrials.gov

Summary

To investigate the effect of liposomal bupivacaine compared with bupivacaine hydrochloride for intercostal blockades for patients undergoing Video-assisted thoracoscopic surgery.

Detailed Description

Video-assisted thoracoscopic surgery (VATS) is a minimally invasive routine procedure. It's less invasive than thoracotomy but postoperative pain is still a problem. At Aalborg University Hospital, intercostal blockades with bupivacaine is used as standard pain treatment for patients undergoing VATS. Adding adjuvants to the blockades may prolong the effect. The aim of this study is to examine if intercostal nerve blockades with liposomal bupivacaine improves postoperative pain management compared to intercostal nerve blockades with bupivacaine hydrochloride.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults independent of sex with an age of ≥ 18 years
•Patients undergoing VATS as a part of either examination or treatment of lung cancer

Exclusion Criteria

•Patients who are unable to understand oral and written information.
•Patients with known chronic pain in the thorax which have been persisting for at least six months before the day of surgery.
•Pregnant and nursing women.
•Patients with hypersensitivity / allergy / Intolerance to dexamethasone or bupivacaine.
•Patients receiving a planned preoperative epidural blockade during their stay.
•Patients converted to open surgery.

Locations (1)

Aalborg University Hospital

Aalborg, Region of Northern Jutland, Denmark

Key Dates

Start Date

September 15, 2021

Primary Completion Date

April 1, 2022

Completion Date

May 31, 2022

Last Updated

September 21, 2021

Enrollment

ESTIMATED participants

Conditions

Postoperative PainLung CancerVideo Assisted Thoracoscopic SurgeryBlockades NeuromuscularAnesthesia, Local

Interventions

Liposomal bupivacaine

DRUG

Bupivacaine Hydrochloride

DRUG

Contacts

Jannie Bisgaard, MD, PhD

CONTACT

97660578 j.staehr@rn.dk

Phillip Sperling, BSc

CONTACT

21141411 phis@rn.dk

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

RECRUITINGPHASE3

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 21, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Magnetic Resonance Imaging of the Lung: Oncological Applications

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)